Search
latrepirdine (Dimebon, dimeboline, dimebolin)
Indications:
- possibily of benefit in Alzheimer's disease
- investigational agent for treatment of Huntington's disease
- used in Russia for decades to treat Alzheimer's disease
- not effective for Alzheimer's disease
Dosage: oral agent
Adverse effects:
- generally safe & well tolerated
- dry mouth
- depression
Mechanism of action:
1) antihistamine
2) weak cholinesterase inhibitor
3) may be neuroprotective
Clinical trials:
- CONNECTION trial
Interactions
drug adverse effects of cholinesterase inhibitors
General
H1 receptor antagonist (antihistamine)
cholinesterase inhibitor
Database Correlations
PUBCHEM cid=197033
References
- Doody RS et al,
Effect of dimebon on cognition, activities of daily living,
behaviour, and global function in patients with mild-to-
moderate Alzheimer's disease: A randomised, double-blind,
placebo-controlled study.
Lancet 2008, 372:207
PMID: 18640457
- LA Times, March 4, 2010
http://latimesblogs.latimes.com/booster_shots/2010/03/dimebon-alzheimers-disease-drug.html
- Pfizer Press Release
Pfizer And Medivation Announce Results From Two Phase 3 Studies
In Dimebon (latrepirdine*) Alzheimer's Disease Clinical
Development Program
http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp?rssUrl=http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp
- Dimebon Clinical Trials
http://www.dimebontrials.com